Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06824532Recruiting

Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life

Role: lead

NCT05895318Completed

Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD

Role: lead

NCT05616923Phase 1Completed

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Role: lead

NCT02972996Not ApplicableCompleted

Blueberry Consumption and Type 2 Diabetes

Role: lead

All 4 trials loaded